Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma
Journal of Clinical Oncology · 01.02.2023 · 41 (4) · 745-755
DOI: 10.1200/jco.22.00597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.02.2023. Verfasst von Jason Westin und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Piperidines, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL, particularly in the non–germinal center B-cell-like subset. METHODS We enrolled 60 patients with newly diagnosed non–germinal center B-cell-like DLBCL in this investigator-initiated, single-arm phase II trial of rituximab, lenalidomide, and ibrutinib (RLI) with the sequential addition of chemotherapy (ClinicalTrials.gov identifier: NCT02636322 ). Patients were treated with rituximab 375 mg/m 2 intravenous once on day 1, lenalidomide 25 mg once per day on days 1-10, and ibrutinib 560 mg once daily continuously of each 21-day cycle (RLI). After two cycles, standard chemotherapy was added to RLI for six additional cycles. The primary end points were overall response rate (ORR) after two cycles of RLI alone and complete response rate after completion of RLI with chemotherapy. In evaluable samples, circulating tumor DNA and DLBCL90 assays were performed. RESULTS The median age was 63.5 years (range, 29-83 years) with 28% age 70 years or older. The revised international prognostic index identified 42% as high risk, and 62% were double expressor of MYC and BCL2 protein. The ORR after two cycles of RLI was 86.2%, and the complete response rate at the end of RLI-chemotherapy was 94.5%. With a median follow-up of 31 months, the progression-free survival and overall survival were at 91.3% and 96.6% at 2 years, respectively. CONCLUSION Smart Start is the first study, to our knowledge, to treat newly diagnosed DLBCL with a targeted therapy combination before chemotherapy. RLI produced a high ORR, and RLI with chemotherapy resulted in durable responses. This establishes the potential for developing biologically driven and noncytotoxic first-line therapies for DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Seagen, Bothell, WA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Jason Westin, Fredrick Hagemeister, Hun Ju Lee, Loretta Nastoupil, Alma Rodriguez, Swaminathan P Iyer, Michael Wang, Man Chun John Ma, Francisco Vega, Yang Lu, Sanjit Tewari, David W Scott, Christopher R Flowers, Sattva Neelapu, Michael R Green
Förderung
- NCI NIH HHS
Zitieren
APA
Westin, J., Davis, R. E., Feng, L., Hagemeister, F., Steiner, R., Lee, H. J., Fayad, L., Nastoupil, L., Ahmed, S., Rodriguez, A., Fanale, M., Samaniego, F., Iyer, S. P., Nair, R., Oki, Y., Fowler, N., Wang, M., Ma, M. C. J., Vega, F., …, & Green, M. R. (2023). Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. Journal of Clinical Oncology, 41(4), 745-755. https://doi.org/10.1200/jco.22.00597
Vancouver
Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. Journal of Clinical Oncology. 2023;41(4):745-755. doi:10.1200/jco.22.00597
BibTeX
@article{Westin2023,
author = {Westin, Jason and Davis, R Eric and Feng, Lei and Hagemeister, Fredrick and Steiner, Raphael and Lee, Hun Ju and Fayad, Luis and Nastoupil, Loretta and Ahmed, Sairah and Rodriguez, Alma and Fanale, Michelle and Samaniego, Felipe and Iyer, Swaminathan P and Nair, Ranjit and Oki, Yasuhiro and Fowler, Nathan and Wang, Michael and Ma, Man Chun John and Vega, Francisco and McDonnell, Timothy and Pinnix, Chelsea and Griffith, Donna and Lu, Yang and Tewari, Sanjit and Sun, Ryan and Scott, David W and Flowers, Christopher R and Neelapu, Sattva and Green, Michael R},
title = {Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {4},
pages = {745--755},
doi = {10.1200/jco.22.00597}
}
EUVIMED